© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Dianthus Therapeutics, Inc. (DNTH) shows an Average True Range (ATR) of 2 and an Enterprise Value of N/A. Its average trading volume over the past 3 months is 671.76K, indicating liquidity. These fundamental metrics provide insight into DNTH's underlying financial health and market activity.
Dianthus Therapeutics, Inc. (DNTH) technical indicators as of December 23, 2025: the SMA 20 is 1.62%, SMA 50 at 12.47%, and SMA 200 at 63.38%. The RSI 14 value is 61.52, suggesting its current momentum. These technical analysis signals help assess DNTH's price trends and potential future movements.
Dianthus Therapeutics, Inc. (DNTH) stock performance overview as of December 23, 2025: The 52-week high is $45.46 (currently -3.71% below), and the 52-week low is $13.37 (currently 227.5% above). Over the past year, DNTH's performance is 82.15%, compared to the S&P 500's 10.56% change.
According to market data, Dianthus Therapeutics, Inc. (DNTH) stock's recent performance metrics show that over the last month, DNTH is 7.31%, with a Year-to-Date (YTD) performance of 100.78%. Over the past year, the stock has seen a 82.15% change. These figures summarize DNTH's price movements across various periods, reflecting its historical returns.
According to current financial data, DNTH stock's P/E (TTM) ratio is -12.70, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for DNTH, including P/S (499.29), P/B (2.94), and P/FCF (-14.02), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.